Novartis Investigative Site

Shimonoseki, Yamaguchi 752-0976

0 studies enrolling now · 2 studies all time

What they study most

Polymyalgia Rheumatica, Rheumatoid Arthritis

Studies at this site

• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed